Close Menu

Biodesix

At the European Lung Cancer Conference last week in Geneva, Biodesix presented data from a multi-center Phase III study that showed VeriStrat was able to identify NSCLC patients most likely to have a "significant survival benefit" from treatment with Tarceva.

The results, presented today at the Second European Lung Cancer Conference, indicate that the MALDI-based test could differentiate which patients would benefit from erlotinib treatment and which wouldn't.

Biodesix offers to help pay for the cost of the test for those patients whose doctors have determined they need it, but who don't have adequate insurance coverage.

Molecular diagnostics developer Biodesix has purchased Sapio's Exemplar laboratory information management system.

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.